Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2025 May;237(3):117-140.
doi: 10.1055/a-2556-4302. Epub 2025 May 9.

GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025

Thorsten Simon  1 , Theresa Thole  2 , Sveva Castelli  2 , Beate Timmermann  3 , Danny Jazmati  4 , Rudolf Schwarz  5 , Jörg Fuchs  6 , Steven Warmann  7 , Jochen Hubertus  8 , Matthias Schmidt  9 , Julian Rogasch  10 , Friederike Körber  11 , Christian Vokuhl  12 , Jürgen Schäfer  13 , Johannes Hubertus Schulte  14 , Hedwig Deubzer  2 , Carolina Rosswog  1   15 , Matthias Fischer  1   15 , Peter Lang  14 , Thorsten Langer  16 , Kathy Astrahantseff  2 , Holger Lode  17 , Barbara Hero  1 , Angelika Eggert  2
Affiliations
Practice Guideline

GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025

Thorsten Simon et al. Klin Padiatr. 2025 May.

Erratum in

Abstract
in English, German

The clinical course of neuroblastoma is more heterogeneous than any other malignant disease. Many low-risk patients experience regression after limited or even no chemotherapy. However, more than half of high-risk patients die from disease despite intensive multimodal treatment. Precise disease characterization for each patient at diagnosis is key for risk-adapted treatment. The guidelines presented here incorporate results from national and international clinical trials to produce recommendations for diagnosing and treating neuroblastoma patients in German hospitals outside of clinical trials.

Der klinische Verlauf von Neuroblastomen ist sehr variabel. Bei Patienten mit günstigem Risikoprofil werden regelhaft Spontanregression der Tumoren beobachtet. Bei Hochrisiko-Neuroblastom können dagegen nur ca. 50% der Patienten durch eine intensive multimodale Therapie geheilt werden. Eine exakte Risikoklassifizierung jedes einzelnen Patienten ist von entscheidender Bedeutung eine korrekte risikoadaptierte Therapie. Die hier vorgestellten Empfehlungen berücksichtigen Ergebnisse von nationalen und internationalen klinischen Studien und definieren den gegenwärtigen Standard für die Behandlung von Patienten mit Neuroblastomen in Deutschland außerhalb von klinischen Studien.

PubMed Disclaimer

Conflict of interest statement

Thorsten Simon reports grants in form of institution payments from Deutsche Kinderkrebsstiftung; consulting fees from Recordati Rare Diseases, Norgine Ltd. and Merck; and is a member of the steering committee of the SIOP Europe Neuroblastoma (SIOPEN) Executive Committee, SIOPEN Clinical Trials Committee and GPOH Executive Committee (until 31.12.2024), for which he receives no payment. Matthias Schmidt received speaker honoraria from Recordati Rare Diseases. Julian Rogasch received speaker honoraria from GE Healthcare GmbH, Novartis Radiopharmaceuticals GmbH and Hexal AG. Christian Vokuhl received speaker honoraria from Recordati Rare Diseases. Jürgen Schäfer received honoraria as lecturer from Philips HC. Hedwig E. Deubzer received speaker and advisory board honoraria from Recordati Rare Diseases. Matthias Fischer institution payments from the Federal Ministry of Education and Research Germany; grants or contracts in the form of institution payments from AstraZeneca, Bayer, Eli Lilly and Company, and Novartis; consulting fees from Bayer; and is a member of the steering committee of the Advances in Neuroblastoma Association, for which he receives no payment. Holger Lode obtained honorary fees for lectures and advisory boards from Recordati Rare Diseases, BeiGene, FarmaMondo, Newbridge Pharmaceuticals and Biomedica. Angelika Eggert received speaker and advisory board honoraria from Recordati Rare Diseases.

Publication types

LinkOut - more resources